登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 根据《公司法》《上市公司股份回购规则》等相关规定，一心堂药业集团股份有限公司（以下简称"公 司"或"本公司"）通过股份回购专用证券账户持有的本公司股份11,475,900股不享有参与权益分派的权 利。本次权益分派以2024年度权益分派方案实施时股权登记日的总股本585,604,125股扣除公司股份回购 专用证券账户股份数11,475,900股后的574,128,225股为基数，向全体股东每10股派发现金红利3元(含 税)，不送红股，不以资本公积金转增股本，本次预计现金分红总额为172,238,467.50元（含税)。 公司2024年年度权益分派方案已获2025年5月21日召开的2024年年度股东会审议通过，现将权益分派事 宜公告如下： 一、股东会审议通过的权益分派方案情况 1、公司2024年年度股东会审议通过的利润分配方案为：公司决定以2024年度权益分派方案实施时股权 登记日的总股本扣除公司回购专用账户股份数（截至公告披露日，公司股份回购专用证券账户 ...

医药生物 | 证券研究报告 — 调整盈利预测 2025 年 5 月 26 日 605266.SH 买入 原评级：买入 市场价格:人民币 23.01 板块评级:强于大市 股价表现 (%) 今年 至今 1 个月 3 个月 12 个月 绝对 4.8 14.5 6.9 (55.9) 相对上证综指 2.2 12.9 7.8 (63.4) 发行股数 (百万) 154.54 (57%) (44%) (30%) (16%) (2%) 12% May-24 Jun-24 Jul-24 Aug-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 Apr-25 May-25 健之佳 上证综指 | 流通股 (百万) | 154.54 | | --- | --- | | 总市值 (人民币 百万) | 3,556.03 | | 3 个月日均交易额 (人民币 百万) | 68.33 | | 主要股东持股比例（%） | | | 深圳市畅思行实业发展有限公司 | 15.17 | 资料来源：公司公告， Wind ，中银证券 以 2025 年 5 月 23 日收市价为标准 中银国际证券股份有限公司 具备证券投 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总 深圳市海王生物工程股份有限公司近期为以下控股子公司向银行或其他金融机构申请综合授信额度等事 项提供了担保：1. 新疆海王弘康向昆仑银行股份有限公司喀什分行申请不超过人民币3000万元的额度提 供连带责任保证担保。2. 安庆海王向安徽怀宁农村商业银行股份有限公司申请不超过人民币450万元的 额度提供连带责任保证担保。3. 广东海王医疗配送向九江银行股份有限公司广州增城支行申请不超过人 民币900万元的额度提供连带责任保证担保。4. 湖北凯安晨向华夏银行股份有限公司武汉分行申请不超 过人民币1500万元的额度提供连带责任保证担保。5. 浙江海王向渤海银行股份有限公司杭州分行申请不 超过人民币1000万元的额度提供连带责任保证担保。6. 滨州海王向青岛银行股份有限公司滨州分行申请 不超过人民币1000万元的额度提供连带责任保证担保。 截至目前，公司累计担保余额约为人民币48.35亿元，占公司2024年度经审计合并报表净资产的比例为 170.03%，不存在逾期担保的情况。 截至2 ...

Core Viewpoint - The company, Jianzhijia, has shown significant growth in its stock price and is actively expanding its market presence through both self-built and acquired stores, while also focusing on social responsibility and competitive strategies in the healthcare sector [1][2][3]. Group 1: Market Performance - As of May 23, 2025, Jianzhijia's stock closed at 23.01 yuan, a 9.83% increase from the previous week [1]. - The company reached a market capitalization of 3.556 billion yuan, ranking 22nd in the pharmaceutical commercial sector and 3715th in the overall A-share market [1]. Group 2: Store Expansion Strategy - In 2024, Jianzhijia opened 314 self-built stores and acquired 122 stores, resulting in a net increase of 370 stores after closing 66 [2][4]. - The company plans to adapt its expansion strategy based on regional market conditions and policy implementations, emphasizing compliance with national healthcare regulations [2]. Group 3: Social Responsibility Initiatives - Jianzhijia has created approximately 21,000 jobs, focusing on providing opportunities for women and marginalized groups [1]. - The company has engaged in various health education and community support activities, including free health monitoring for over 4 million chronic disease members and significant contributions to public health initiatives [1][4]. Group 4: Competitive Positioning - The company views third-party platforms as partners rather than competitors, leveraging them for data and logistics services to enhance customer reach [3]. - Jianzhijia aims to differentiate itself through unique product offerings, professional services, and brand positioning to maintain a competitive edge in the market [3][4]. Group 5: Corporate Governance - The 2024 annual shareholders' meeting was held on May 21, 2025, with 153 shareholders present, representing 53.24% of the voting shares [5]. - The meeting approved ten resolutions, including financial reports and the appointment of auditing firms, confirming compliance with legal and regulatory standards [5].

Core Viewpoint - China National Pharmaceutical Group plans to acquire 100% equity of Beijing Jinsui Technology Development Co., Ltd. from its controlling shareholder, General Technology Group, for 302 million yuan, aiming to enhance its e-commerce capabilities and transition into a health enterprise [2][6]. Group 1: Acquisition Details - The acquisition involves a cash payment of 302 million yuan, with Jinsui Technology becoming a wholly-owned subsidiary of China National Pharmaceutical [2]. - Jinsui Technology's core business includes low-frequency consumer products like Philips electric toothbrushes and blood pressure monitors, which do not align well with China National Pharmaceutical's high-medical-attribute products [2][6]. Group 2: Financial Performance of Jinsui Technology - Jinsui Technology's revenue has significantly declined from 1.747 billion yuan in 2021 to 1.018 billion yuan in 2023, a drop of 41.73% [4]. - The company's net profit has also decreased, with projections indicating it may fall below 30 million yuan in 2025 [5]. Group 3: Financial Implications for China National Pharmaceutical - The acquisition may require China National Pharmaceutical to raise over 500 million yuan, including the acquisition cost and debt repayment obligations [4][8]. - The company's 2024 net profit was only 323 million yuan, indicating that the acquisition could consume nearly all of its annual profit [8]. Group 4: Industry Context and Challenges - The medical device e-commerce market is highly competitive, with major players like Alibaba Health and JD Health holding over 60% market share, posing significant challenges for Jinsui Technology [6]. - The regulatory environment for pharmaceutical e-commerce is stringent, complicating the transition from consumer electronics to medical e-commerce [5][6]. Group 5: Historical Context and Concerns - China National Pharmaceutical has faced issues with goodwill impairment and performance disputes in past acquisitions, raising concerns about the sustainability of its growth strategy [9]. - The acquisition of Jinsui Technology, a related party transaction, has sparked questions about potential conflicts of interest and the rationale behind diversifying into consumer electronics [10].

北京市朝阳区建外大街甲 14 号广播大厦 5/9/10/13/17 层 北京海润天睿律师事务所 关于九州通医药集团股份有限公司 致：九州通医药集团股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受九州通医药集团股份 有限公司（以下简称"公司"）的委托，指派本所律师出席公司 2024 年年度股 东会（以下简称"本次股东会"），并依据《中华人民共和国公司法》（以下简 称《公司法》）、《上市公司股东会规则》（以下简称《股东会规则》）、《公 司章程》及其他相关法律、法规的规定，就公司本次股东会的召集、召开程序、 出席会议人员的资格、召集人资格、表决程序及表决结果等有关事宜出具本法律 意见书。 对本法律意见书的出具，本所律师特作如下声明：本所及经办律师依据《证 券法》《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务 执业规则》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格履 行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证 本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 一、 ...

药易购股东询价转让，公司深化资本市场布局 金十数据5月23日讯，近日，出让方四川合纵药易购医药股份有限公司股东海南合森投资中心（有限合 伙）、成都市合齐投资管理中心（有限合伙）委托中国国际金融股份有限公司组织实施药易购首发前股 东询价转让。截至2025年5月22日，出让方所持首发前股份的数量为海南合森680万股，持股比例 7.11%，成都合齐143万股，持股比例1.49%。出让方拟转让股份的总数为246.9万股，占药易购总股本的 比例为2.58%，本次询价转让为非公开转让，不通过集中竞价交易方式进行据披露。 （36氪） ...

暗盘资金流向曝光！提前捕捉庄家建仓信号>> 医药商业板块直线拉升，一心堂（002727）涨停，漱玉平民（301017）、健之佳（605266）、第一医药 （600833）、益丰药房（603939）、老百姓（603883）等纷纷走高。 ...

Group 1 - The global exoskeleton robot market is entering a rapid growth phase, with a projected market size of $1.8 billion in 2024 and expected to exceed $12 billion by 2030, reflecting a compound annual growth rate (CAGR) of 28% [1] - China's 14th Five-Year Plan includes exoskeletons as a key development area for high-end medical equipment, with several regions incorporating rehabilitation exoskeletons into insurance reimbursement, which is expected to accelerate commercialization [1] - The medical rehabilitation sector is seeing mature commercialization scenarios supported by policies, with a focus on three main directions: hospital policy support (innovative drugs and devices), expanding public demand (blood products, home medical devices, weight loss drug supply chain), and an upward trend in overseas market cycles (heparin, respiratory joint inspection) [1] Group 2 - The Medical ETF (159828) tracks the CSI Medical Index (code: 399989), which is compiled by the China Securities Index Co., selecting listed companies in the medical device, medical services, and pharmaceutical commercial sectors to reflect the overall performance of related securities [1] - The CSI Medical Index has strong industry representation, with the latest trading day showing an increase of 0.95%, serving as an important reference for investors looking to allocate in the healthcare industry [1] - Investors without stock accounts can consider the Guotai CSI Medical ETF Connect A (012634) and Guotai CSI Medical ETF Connect C (012635) [1]

Group 1 - The Shanghai Composite Index fell by 0.17%, and the Shenzhen Component Index decreased by 0.19%, while the ChiNext Index opened flat, indicating an adjustment in high-position stocks [1] - Nearly 1,500 listed companies have announced share buybacks this year, with a total buyback amount exceeding 110 billion yuan, and over 880 companies have actually repurchased shares, totaling more than 60 billion yuan [1] - CITIC Securities emphasizes that free cash flow is a core indicator of financial quality, useful for returning dividends to shareholders, implementing stock buybacks, optimizing capital structure, strategic expansion, and building financial safety nets [1] Group 2 - The lowest fee tier free cash flow ETF (159201) closely tracks the National Certificate Free Cash Flow Index and has shown strong long-term performance [1] - The cash flow stock selection strategy has good allocation value, with a significantly different holding structure compared to traditional dividend strategies, making it a strong offensive strategy in value markets and an excellent complement to defensive strategies [1]